U.S. markets open in 1 hour 41 minutes
  • S&P Futures

    4,409.00
    +19.50 (+0.44%)
     
  • Dow Futures

    34,950.00
    +118.00 (+0.34%)
     
  • Nasdaq Futures

    15,022.25
    +66.50 (+0.44%)
     
  • Russell 2000 Futures

    2,240.80
    +19.20 (+0.86%)
     
  • Crude Oil

    72.96
    -0.99 (-1.34%)
     
  • Gold

    1,810.70
    -6.50 (-0.36%)
     
  • Silver

    25.48
    -0.07 (-0.28%)
     
  • EUR/USD

    1.1886
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    1.2390
    0.0000 (0.00%)
     
  • Vix

    18.45
    +0.75 (+4.24%)
     
  • GBP/USD

    1.3898
    -0.0009 (-0.06%)
     
  • USD/JPY

    109.5710
    -0.0440 (-0.04%)
     
  • BTC-USD

    39,573.07
    -1,976.38 (-4.76%)
     
  • CMC Crypto 200

    964.72
    +14.82 (+1.56%)
     
  • FTSE 100

    7,084.49
    +52.19 (+0.74%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology

·1 min read
  • Enochian BioSciences Inc (NASDAQ: ENOB) has acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.

  • The technology is delivered by a nanoparticle, allowing it to either rapidly treat an infection or to wait in ambush for a cell to become infected to prevent (prophylaxis) future infections.

  • Since the target cells of the viruses live up to 20 months in human airways, it is possible that a single inhalation could both rapidly treat and protect against infection for relatively long periods.

  • Recently, the FDA accepted Enochian's pre-IND request for a potential functional cure or treatment of HIV.

  • The request was based on the results of a 54-year man living with HIV who had failed to suppress the virus with antiviral therapy.

  • Last week, the company also announced a million direct offering.

  • Price Action: ENOB shares are up 13.8% at $6.60 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.